This study aimed to evaluate the change in lower urinary tract symptoms and QoL after combination therapy of solifenacin and mirabegron in patients with benign prostatic hyperplasia presenting with persistent storage symptoms after treatment tamsulosin.

The researchers evaluated the IPSS, OABSS, prostate-specific antigen, prostate volume, Qmax, and PVR before and after treatment. Patients showing baseline OABSS ⩾3 were included and treated with tamsulosin 0.2 mg as an initial drug for one month. After one month, add-on treatment was provided to patients who did not show improvement in OABSS with tamsulosin 0.2 mg. After two months, we evaluated changes in OABSS, IPSS, Qmax, and PVR.

There were no significant differences observed between patients receiving add-on treatment with solifenacin and those receiving mirabegron after therapy. The IPSS QoL scores improved in patients treated with mirabegron and tamsulosin more than those treated with solifenacin and tamsulosin.

The study concluded that a combination of tamsulosin and mirabegron might improve the QoL of patients presenting with persistent storage symptoms after tamsulosin monotherapy. Better QoL due to mirabegron compared with solifenacin could be associated with fewer adverse effects, such as dry mouth and constipation.